Symposium booklet 2016

Proffesional Services In All Spheres Of Healthcare

M. P. SHAH HOSPITAL

20 2016

SESSION IPAEDIATRIC INFECTIONS

SESSION IIFUNGAL

INFECTIONS

SESSION IIIBACTERIAL

INFECTIONS

SESSION IVHAEMORRHAGIC

VIRAL FEVERS

SESSION VNEGLECTED INFECTIONS

Professional Services In All Spheres Of Healthcare2

M.P. SHAH HOSPITAL UPDATE

M.P. Shah Hospital is a Social Service league Hospital which has been in existence for the last 83 years, as a ‘not for profit’ organization. The Hospital has one single social objective of providing quality, affordable health care services to the community at affordable costs. It is a multi-super-specialty, state-of-the art, tertiary care hospital with a current capacity of 210 fully operational beds, 30 dedicated critical care beds, 10 renal dialysis units and 12 chemotherapy units. It provides all the modern out-patient and in-patient facilities with dedicated pavilions/ wards, specialty clinics, advanced radiology, pathology and Cath lab operations. We are going through exciting times of development and redefining the way health care is delivered in East and Central Africa region.

Professional Services In All Spheres Of Healthcare 3

CONTENTS

Symposium Schedule

Message from the Chairman

Message form the CEO

Message From the Symposium Chairman

Speakers Profiles

Panelists Profiles

Hospital Update

Sponsors Acknowledgement

Notes

Symposium Committee Members

04 - 05

06

07

08

09 - 15

16 - 20

21 - 32

33 - 40

41- 42

43


SESSION TIME TOPIC SPEAKER CHAIRSSCHEDULE

SESS

ION

I (P

fizer

) 07 30

07 40

08 00

08 20

08 40

09 30

09 50

10 10

10 30

10 50

11 30

11 50

12 10

12 30

12 50

13 10

13 40

09 00

11 20

Opening Ceremony

Update on TB diagnostics

New paradigm in the treatment of tuberculosis

Invasive candidiasis

Aspergillosis

Intersession Break / Q & A

Chairman of The M.P. Shah Hospital

Recent advances in management of

H-pylori disease in children

Hepatitis C - (Are we nearing cure)

IPC programme at M.P. Shah Hospital


TEA BREAK

Emerging trends in hospital infections

Science behind antibiograms & antibiotic guidelines

Molecular epidemiology of MRSA

How would I manage multi - resistance gram

negative organisms - New Horizons

Use of Immunodulators in Sepsis and Severe Sepsis


LUNCH BREAK

Dr. S Patel

Dr. C Mwachari

Dr. M Chakaya

Dr. E Oundo

Prof. R Adam

Dr. M Shah

Dr. A Laving

Dr. R Shah

CNI F Kamau

Dr. D Silverstein

Dr. L Achieng’

Dr. G Omuse

Dr. E Omonge

Dr. R Jaju

Prof. R Adam

&

Dr. S Dhirane

Prof. G Revathi

&

Dr. H Saha

SESS

ION

II (M

SD)

SESS

ION

III (A

stra

Zene

ca)

Prof. G Lule

&

Dr. B Samia


SESSION TIME TOPIC SPEAKER CHAIRS

SCHEDULE

Each session is worth 5 CPD points

14 10

14 30

14 50

15 10

15 30

16 00

16 30

16 50

16 10

17 10

17 30

18 00

Prof. G Revathi

Dr. J Wachira

Dr. A Agweyu

Dr. R Virani

Dr. S Mauro

Prof. O Anzala

Prof K Bhatt

Dr. C Abeid

Mr. A Das

Dr. M Lumba

&

Dr. J Mbuthia

SESS

ION

V (G

etz)

Pediatric UTI and implications for anti microbial

stewardship

New Born Sepsis - What is new

Management of pneumonia - WHO classification

and treatment

Prevention of pneumococcal diseases and the

role of currently available vaccines.


Afternoon Tea Break

Synopsis of arbo virus infections in Kenya with

special interest to chickungunya and dengue virus.

Update on Zika VIrus

Update on Kala Azar

Clinical continuum Chronic kidney disease and

infectious diseases


CEO’s vote of thanks

SESS

ION

IV (G

laxo

)

Dr. J Aluoch

&

Dr. A Shah


Dr. Manoj Shah

FROM THE CHAIRMAN I M.P. Shah Hospital

Dear Participants,On behalf of the M.P. Shah Hospital we wish to warmly Welcome you to the M. P. Shah Hospital 5th Annual Symposium. This is a great opportunity for us to host you, as you attend, participate and network at this symposium. I wish to sincerely thank and appreciate, Dr. S.T. Patel for his leadership and vision for making this symposium truly international.Previous symposiums have seen many hospitals positively impact the community with information that has helped improve healthcare practices throughout the country. We note with concern that infectious disease are still a major healthcare burden in the developing world. Evolving resistance and a profound lack of new antibiotics further compound the situation. These concerns were the driving force behind the introduction of the M. P. Shah Hospital INFECTIOUS DISEASES Symposium, a forum that would begin to address the aforementioned challenges and increase awareness on current best practice, trends and technologies.Over eighty years have passed since M. P. Shah Hospital began as a simple nursing home to provide quality, affordable healthcare services to the community. We have since grown into a fully-fledged hospital providing a variety of health services. This high level of service has been our hallmark for the past eight decades, and has remained consistent as we touch lives and bring hope to many in the region. The past few years have seen significant progress for the Hospital, both in terms of its physical infrastructure as well as its systems and processes. These changes have continued to align the hospital as a center of excellence for quality healthcare in the region. A key development is the commencement of complete Paediatric services in the newly built state-of-the-art Suryakala Maganlal Chandaria Children’s Medical Center. This brand new children’s hospital is a 5 storey center offering both Outpatient and Inpatient Paediatric services including Neonatal and Paediatric ICU as well as private rooms for children separated by age category. A resident team of Paediatrically-trained doctors and nurses run the service, including a Paediatric Intensivist. In addition, the hospital has completed an additional 5 storey tower as part of its long-term development. The Dr. Kanubhai Babla Medical Center, houses our brand new ICU, Theatre, Cardiac Diagnostic Center and Cath Lab, along with executive private patient rooms. The Hospital is going through an exciting phase of development and it has launched a brand new Cardiac Center focused towards improving lifestyle diseases related to heart like hypertension, stroke, angina, hyperlipidemia, diabetes etc. The Dr. Rasik Kantaria Cardiac Center is located on the 5th floor of the Dr. Kanubhai Babla Medical Center. It is a world-class medical center offering the complete range of advanced cardiac diagnostics and medical treatment options for adults and children with heart related diseases. This Cardiac Center is managed by world class doctors and a team of expert technicians and trained nurses.

With all these developments as well as those in the pipeline, the Hospital is poised to take its place as a center of excellence for outstanding healthcare in the region. For this remarkable service I extend the leadership’s most sincere gratitude and appreciation to you all. This success would not be possible without your support over the years. M. P. Shah Hospital stands tall on your shoulders.

I wish you good deliberations at this symposium.


Mr. Anup Das

FROM THE C.E.O. I M.P. Shah Hospital

On behalf of the Board, Management and Organizing Committee, of The Social Service League, M.P.Shah Hospital, I am delighted to welcome all the Distinguished Speakers, Corporate sponsors , Exhibitors, Stakeholders and Delegates to the M.P. Shah Hospital’s 5th infectious diseases symposium. This is one of the Hospital’s largest annual events which has gained prominence with every passing year with its particular objective in providing a successful forum for researchers and clinicians from all over the region, to showcase very informative and interesting case studies as well as exchange ideas on Infectious Diseases, with the goal of providing the best possible care for our patients and communities. This symposium will give participants a platform to discover novel opportunities, meet with colleagues, and broaden their knowledge.I also welcome you to come and see the new infrastructure of M.P. Shah Hospital and witness the change in providing world class healthcare, infrastructure and services. Please visit the following new developments in this hospital:-

• New State of the art Children’s hospital with its own 24 hours casualty, Well-baby center, Sub Specialty clinics, NICU, PICU & PHDU.

• New State of the art, most modern Intensive Care Unit and High Dependency Unit set up in the region, at the ground floor of Dr. Kanubhai Babla Medical Center.

• New cardiac center with specialized cardiac diagnostics and state of the art Cath Lab doing all kinds of interventional cardiac procedures.

• New executive and private rooms at the 2nd and 3rd floor of Dr. Kanubhai Babla Medical Center.• New Laminar floor theatre at the 1st floor of Dr. Kanubhai Babla Medical Center.• New 3 Tesla MRI, 128 Slice Cardiac CT Scan, digital X Ray, Mammography, 4D Ultrasounds and OPG

units in the radiology center.• Automated hematology analyzer, New fully automated Biochemistry equipment, Fully Automated

microbiology unit & automated Histopathology units in the Pathology Lab. Our laboratory is able to perform more than 5000 different kinds of tests.

• Brand new dental center with maxillofacial and orthodontic specialties.• Brand new ENT center with all modern equipment, possibly the best in East and Central Africa region

and Audiology Unit.• A modern wound management clinic and trauma center at the Accident and Emergency unit.• Renal center with advanced Dialysis units, CRRT machines and Kidney transplant unit.• We are doing all kind of Orthopedic implants, replacement surgeries, Neuro & Spine procedures• Our Maternity center gives birth to on average 150 babies every month and it is growing every day.• Our Accident & Emergency unit receives around 6000 patients every month and is improving every

day.• We have state of the art oncology management unit with Chemotherapy, Oncology surgeries, in

patient management & Palliative care.

I look forward to your participation in the sessions and I encourage you to take advantage of the wealth of knowledge offered by our speakers and participate in the interactive sessions, as we strive to grow by building a cohesive, cooperative healthcare system.


FROM THE CHAIRMAN I Infectious Disease Symposium

Dr. S. Patel

Once again it’s August and it’s time for the 5th infectious diseases symposium, and On behalf of the Organizing Committee, I would like to warmly welcome you all to the M.P. Shah Hospital’s 5th infectious diseases symposium.

Sub-Saharan Africa has borne the major brunt of infectious disease, including HIV-AIDS, Ebola and now Zika is with us. Keeping up with this theme we now have the 5th edition of the Infectious Diseases Symposium. This symposium is one of the Hospital’s largest annual events and it serves as a forum to facilitate interdisciplinary scientific discussions on various aspects of infectious diseases management. It is recognized by the Medical Practitioners & Dentist Board for CME accreditation and we are confident that it shall provide a unique Educational experience, through the distinguished presenters. They will focus on the impact of change on clinical and laboratory aspects of infectious diseases as well as the current burden of infectious diseases in global public health as well as the changing pathogenic landscape due to emerging and re-emerging infections. These sessions will also cover current challenges and future trends in infectious disease diagnostics.

The symposium will provide you with a unique opportunity to learn about the global trends and most significant developments in infectious diseases, as well as to network with a vast group of diagnostics experts, clinicians and opinion leaders. This year we expect over 500 Senior Medical Professionals to attend the symposium. Today is a result of months of planning by the dynamic, young, organizing committee who have seen this event through to the end while adding quality to every aspect.

Lastly the success of this Programme would not have been possible without the tireless work of the speakers and chairpersons today. A special debt of gratitude goes to the Chairman of M.P. Shah Hospital Dr. Manoj Shah and his board whose total support allows this symposium to go from strength to strength. Thanks to the Hospital C.E.O Mr. Anup Das and his administration team for their moral support and effort in making this event a success. We also thank all our sponsors without whose support this event would not have been suuccessful.

We look forward to a very stimulating and engaging event. Any feedback for an improved symposium will be well received.


SPEAKERS PROFILES & ABSTRACTS I Session I: Paediatric Infections

Dr. J Wachira

Senior Consultant Paediatrician - M.P Shah HospitalFellow of the Royal College of Paediatrics & Child Health-UKM.Med Paediatrics & Child Health/MBChB- University of NairobiExecutive Board member- Kenya Paediatrics Association- (KPA)Ex- Temporary advisor World Health Organization (WHO) in neonatal and pediatrics acute care management

Ambrose is a Kenyan paediatrician with Masters training in epidemiology, based at the KEMRI-Wellcome Trust Research Programme in Nairobi. Working closely with the Kenya Ministry of Health in 2009, his early research involved conducting systematic reviews for a national exercise to adapt the World Health Organization paediatric clinical practice guidelines using the GRADE methodology. Following this, Ambrose was invited to support similar exercises in Uganda and Rwanda. More recently, he was the principal investigator on a large pragmatic clinical trial comparing antibiotic treatments for childhood pneumonia. The findings of this study contributed towards a recent major revision in the Kenyan guidelines, and are likely to eventually influence practice in the region. As he approaches the end of his PhD studies, he is currently considering future areas of work that build on his interest in conducting pragmatic trials for interventions to improve the care and outcomes of hospitalized children in sub-Saharan Africa.

Case Management of Childhood Pneumonia: Revised WHO and Kenya Ministry of Health Classifications and TreatmentChildhood pneumonia claims over one million lives annually and is a leading cause of morbidity worldwide. The case management guidelines for childhood pneumonia currently in use in Kenya and many other countries in sub-Saharan Africa were developed by the World Health Organization (WHO) have been credited for contributing towards substantial reductions in pneumonia deaths. There is however uncertainty over the effectiveness of the guidelines in the current era against a background of the introduction of vaccines targeting Haemophilus influenzae type B and Streptococcus pneumoniae - the leading causes of bacterial pneumonia in children. Results from clinical trials conducted in predominantly Asian populations demonstrating clinical equivalence between amoxicillin and benzyl penicillin led to a revision of the WHO pneumonia guidelines in 2013. However, Kenyan policy makers declined to support a similar change in the local guidelines in the absence additional supportive evidence from African populations citing concerns of high mortality in Africa. We conducted conducting a multi-centre pragmatic clinical trial to compare the effectiveness of the two antibiotics. A total of 527 children aged 2–59 months with severe pneumonia as defined in the 2005 WHO guidelines were recruited from 6 public hospitals across Kenya. The risk of treatment failure was 7.7% in the amoxicillin arm and 8.0% in the benzyl penicillin arm at 48 hours in per-protocol analyses (risk difference, −0.3% [95% CI, −5.0% to 4.3%]), indicating non-inferiority within the pre-specified margin of 7% at 48 hours. Similar results were obtained in intention-to-treat analyses. Mortality was low (0.8%) and comparable to reported findings of the previous trials conducted in Asia that informed the WHO technical updates in 2013.

The findings of this study offer important evidence for policy makers in sub-Saharan African considering the local adaptation of the recent global recommendations for the management of childhood pneumonia. This work has been used to inform a 2014 national guideline panel meeting that revisited the Kenyan guidelines on treatment of pneumonia. The panel reviewed the available evidence, including an updated systematic review that included the Kenyan trial results. Draft recommendations to change policy based on this trial and other evidence were presented to the Ministry of Health and accepted as new national treatment guidelines in early 2015.

New Born Sepsis

Dr. A Agweyu


SPEAKERS PROFILES & ABSTRACTS I Session I: Paediatric Infections

Dr. A Laving

Dr. A Laving is the Program Coordinator for undergraduate students, Department of Paediatrics & Child Health, University of Nairobi. Responsible for making the undergraduate teaching program, from lecture schedule, tutorial topics to clinical teachings in the wards as well as co-ordinating their ward, newborn unit and child health rotations.Participate in teaching paediatric residents, medical and nursing students, supervising research protocols of residents, development of undergraduate and postgraduate programs and preparing examinations for the Department of Paediatrics and Child Health at the University of Nairobi. Participate in running of the paediatric gastroenterology and general paediatric services at Kenyatta National Hospital. Conduct major teaching ward rounds, a general paediatric outpatient clinic and a paediatric gastroenterology/liver clinic once a week, as well as weekly clinical bedside teaching sessions with fourth year medical students and paediatric residents. Consulted for all paediatric GIT issues at the national referral and teaching hospital. Perform diagnostic and therapeutic upper and lower endoscopies and supervise percutaneous liver biopsies on children.

Dr. R. Shah

Dr. Reena Shah is the Interim Chair of the Department of Medicine, AKUHN. She is an Assistant Professor of Medicine and Section Head for Infectious Diseases. Dr. Shah completed her MBBS at the University of Southampton, UK and had been a member of the Royal College of Physicians (MRCP) London since 2000. She obtained a Diploma in Infectious Diseases from the University of London as well as a Diploma in Tropical Medicine from the London School of Hygiene and Tropical Medicine. Following this she obtained a Masters in Infectious Diseases from the University of London. She was awarded Fellowship to the Royal College of Physicians Edinburgh FRCPE in 2014. Her clinical research interest is primarily in the area of HIV/AIDS and hepatitis B. She is currently Chair of the Antibiotic Sub-Committee of the Pharmacy and Therapeutics Committee and also the Vice-Chair of the Kenya HIV Clinicians Association and member of the British HIV Association.

Dr. L Achieng’

Dr. L Achieng’ Is a Physician and Infectious Disease Specialist. She Is a Lecturer in Internal Medicine at the University of Nairobi and an Adjunct Assistant Professor of Medicine at the University of Texas Medical Branch. She heads the Infectious Diseases Unit at the Kenyatta National Hospital and is a member of several Antibiotic stewardship committees and the National Antimicrobial Stewardship Advisory Group.Research interests include improving outcomes in sepsis, antimicrobial stewardship and in cardiovascular disease in HIV

Antibiotics are among the most commonly prescribed medications and this has led to an increase in development of drug resistance. Increasing resistance makes selection of appropriate empiric antibiotics more challenging. As the global community grapples with the emergence of multi drug resistant organisms, it is imperative that all health facilities develop appropriate antibiograms to guide the activities of antibiotic stewardship committees. The onus remains on clinicians to prescribe antibiotics only when necessary and for the shortest duration possible. In this session we will look at the science of antibiograms and how these should guide our practice as clinicians

Recent advances in management of H-pylori disease in children



SPEAKERS PROFILES & ABSTRACTS I Session II: Fungal Infections

Dr. E Omonge

Dr. Omonge is qualified in MBChb (Nairobi) and MMed (Nairobi)He is a leading authority in clinical therapeutics and pharmacology.He has an interest in HIV medicine and a respected member of the faculty at the University of Nairobi.He is the general secretary of society of AIDS in Africa and the Kenya HIV Clinicians AssociationHe has authored numerous research articles in the field of HIV and Diabetes.

Dr Enoch Omonge is a lecturer in the department of Clinical Medicine and therapeutics, thematic unit of Clinical Pharmacology. His special interest is HIV Medicine and Rational Antimicrobial use . Has contributed to developing Antibiotherapy protocols and HIV care at the KNH. Current research interest is HIV associated coinfections and comorbidities

Dr. G Omuse

Dr. Geoffrey Omuse is an Assistant Professor and Consultant Clinical Pathologist at the Aga Khan University Hospital Nairobi. He has very diverse research interests including several publications on infections due to Staphylococcus aureus in Kenya. In 2013 he completed a month long training on molecular typing of Staphylococcus aureus as part of a technology transfer grant at Tygerberg Hosital, Stellenbosch University, South Africa.

Title: MRSA in Kenya-Filling the gapSeveral studies looking at the prevalence of MRSA in Kenya have been published. However, there is a paucity of knowledge on the molecular epidemiology of MRSA in Kenya and indeed East Africa. Understanding the molecular epidemiology is necessary in order to better assess the relationship between circulating strains and propensity to cause disease. This also helps when investigating MRSA outbreaks and in evaluating the effectiveness of infection control measures put in place to prevent and control MRSA outbreaks.

Dr David Silverstein is a Consultant Cardiologist and an Internist at the Nairobi Hospital for the last 30 years. He came to Kenya in 1974 as a lecturer and then senior lecturer in the University of Nairobi and subsequently Chief Cardiothoracic physician for the government of Kenya. He entered private practice in 1981 and has served on the Medical Advisory Committee and was elected member of the Board for 17 years.He got his MD degree for the University of Chicago and then went to the University of Washington for his internal medicine residency and Cardiology fellowship. He is a Fellow of the American College of Cardiology (FACC) and the American college of Physicians (FACP).Dr. D Silverstein

Imerging trends in hospital infections


SPEAKERS PROFILES & ABSTRACTS I Session II: Fungal Infections

Dr. E Oundo

Dr. Oundo graduated in 2013 from Moi University with M.B.Ch.B after which he joined Tenwek Hospital in 2014 for internship. In 2015, he worked in casualty department in Longisa County referral hospital in 2015. He then moved to MPSHAH hospital where he currently works as a medical officer in HDU/ICU department. He has a deep interest in internal medicine.

Problem; candidiasis is a common and important problem affecting critical care set ups in our facilities. Cause: the most common species is C. albicans, but there are increasing isolation of C. glabrata, C. krusei and C. parapsilosis. There are multiple risk factors, including an ICU patient, immunocompromised, neutropenia, recent surgery, and central catheters. These factors also increase the risk of contracting fluconazole-resistant strains.Manifestation: infection is usually from GIT penetration, biofilms, localized focus, and colonization, which lead to hematogenous spread. It can then affect multiple organs and organ systems: osteoarticular, endophthalmitis, periotonitis and abdominal infections, pneumonia and empyema, mediastinitis, hepatosplenic involvement, and candidemia.Diagnosis: the main diagnostic modalities are blood culture, biopsy, beta-D-glucan assay, PCR, colonization index and candida score. Susceptibility testing is important for streamlining therapy, de-escalation and following of resistance patterns.Treatment mainly involves adequate source control and proper choice of antifungals. Antifungal choice will depend on resitance patterns, culture results, and the underlying status of the patient. The arsenal is azoles, echinocandins, and amphotericin B.Mortality ranges from 30-60% depending on time of initiation of antifungals and severity of the infection. Outcomes are worse with tumors, neutropenia and higher APACHE II scores.

Dr. Oundo Emmanuel Owiti,

M.B.Ch.B, 2013,

MP SHAH Hospital HDU/ICU Medical officer

Abstract

Problem; candidiasis is a common and important problem affecting critical care set ups in our facilities.

Cause: the most common species is C. albicans, but there are increasing isolation of C. glabrata, C. krusei and C. parapsilosis. There are multiple risk factors, including an ICU patient, immunocompromised, neutropenia, recent surgery, and central catheters. These factors also increase the risk of contracting fluconazole-‐resistant strains.

Manifestation: infection is usually from GIT penetration, biofilms, localized focus, and colonization, which lead to hematogenous spread. It can then affect multiple organs and organ systems: osteoarticular, endophthalmitis, periotonitis and abdominal infections, pneumonia and empyema, mediastinitis, hepatosplenic involvement, and candidemia.

Diagnosis: the main diagnostic modalities are blood culture, biopsy, beta-‐D-‐glucan assay, PCR, colonization index and candida score. Susceptibility testing is important for streamlining therapy, de-‐escalation and following of resistance patterns.

Treatment mainly involves adequate source control and proper choice of antifungals. Antifungal choice will depend on resitance patterns, culture results, and the underlying status of the patient. The arsenal is azoles, echinocandins, and amphotericin B.

Mortality ranges from 30-‐60% depending on time of initiation of antifungals and severity of the infection. Outcomes are worse with tumors, neutropenia and higher APACHE II scores.

Festus Kamau is a Clinical Nurse Instructor, and a lead Diabetic Nurse at the M.P. Shah Hospital. Has previously worked at the Aga Khan University Hospital and The Nairobi Hospital.He is trained in Critical Care and has interest in the Infection Control.He got his training from the Kenya Medical Training College Nursing School.He is a member of the Critical Care Nursing Chapter and Infection Control Nursing Chapter.

It is the discipline concerned with preventing healthcare-associated infections within a healthcare facility.As such, it is a practical (rather than an academic) sub-discipline of epidemiology.It is an essential (though often under-recognized and under-supported) part of the infrastructure of health care.Infection prevention and control is akin to public health practice, practiced within the confines of a particular health-care delivery system rather than directed at society as a whole.

CNI F Kamau


SPEAKERS PROFILES & ABSTRACTS I Session IV: Haemorrhagic Viral Fevers

Dr. S Mauro

Prof. O Anzala

Dr. Mauro was born in Torino on 14th April, 1952. He Graduated in Medicine with honours at the University of Torino in November, 1977. Post graduated in Tropical Medicine with honours in Rome University. Came to Kenya in 1980 and worked for field experience at the Mathari Consolata Missionary Hospital. He joined The Nairobi Hospital Medical team in 1982 and in 1985 joined Dr. Philip Rees in full private practice. Since then he has been working as a specialist in the Tropical and Travel Medicine field. He is an author of many publications in several internationally renowned journals and has been an invited speaker to International Congresses in New York, Florence, Venice, Budapest and Canada. Malaria is his main interest. He has been instrumental in bringing the Artemisinin derivative in Africa and the first one to use Artemether in Kenya in 1999. He has been a member of Malaria Task Force and Malarone Project.

Prof. Anzala is the Technical Advisor, Kenya Medical Laboratory Technicians & Technologists Board.Reviewer, East African Medical Journal. Project Manager, Kenya AIDS Vaccine Initiative (KAVI), Department of Medical Microbiology, University of Nairobi.Advisor, Biomedical and Clinical Science Working Group of African AIDS Vaccine Program (AAVP) WHO, UNAIDS.Advisor / Consultant, National Polio Eradication Expert Committee (NPEC), Ministry of Health, Kenya.Advisor, African Childhood Vaccine Program.Advisor, Merck Vaccine Network – Africa.Consultant Virologist / Immunologist, Medical Research Council (MRC) UK, on HIV / AIDS Vaccines in Kenya.Medical Officer 11 Kapsabet District Hospital, Kapsabet, Kenya.Medical Officer 1 Machakos Provincial Hospital, Machakos, Kenya.

Board Certified Nephrology & Internal Medicine Dr. Abeid received his medical degree from the University of Nairobi, college of Health Sciences in Kenya. He did his internship and residency in internal medicine at GBMC and John Hopkins in Baltimore, Maryland USA. During his final year of residency, he was selected to be chief resident in internal medicine residency. Dr. Abeid did his fellowship in nephrology at Yale University in, New Haven Connecticut-USA. He is board certified both in nephrology and internal medicine. Dr Abeid was also a Clinical Assistant Proffessor of Medicine at SUNY Medical School in New York -USA. Dr. Abeid has also taken a keen interest in hypertension and is a hypertension specialist certified by American Society of Hypertension (ASH). He specializes in all aspects of chronic kidney disease, hypertension, polycystic kidney disease, all modalities of dialysis and care of pre and post kidney transplant patients.He sees all his patients at MP shah HospitalDr Chris is currently the Medical director of MP shah Hospital

Dr. C Abeid

CKD and infectious disease continuumThe talk will focus on relation ship betweek CKD and both chronic infectious diseases (CID) and acute infectious diaseases(AID).The question is:Is CKD a risk multiplier for CKD?Vaccination strategies in CKD will also be highlighted.


Update on Zika virus


SPEAKERS PROFILES & ABSTRACTS I Session IV: Haemorrhagic Viral FeversProf. Bhatt was born in Kenya and is a professor of internal medicine in the department of clinical medicine and therapeutics of the university of Nairobi. She did her masters in internal medicine from the University of Nairobi and specialized in tropical medicine from London school of Hygiene and Tropical Medicine. She did her training in bio Ethics from University of Washington. Currently she is the chair of National Bioethics committee of Kenya. She has also been a member of ethics committee of Kenya Medical Research institute and chair of ethics and research committee of university of Nairobi. She has been a council member of National council of science and technology of Kenya. She is a member of scientific advisory committee of Drugs for Neglected Diseases Initiative. Has been a recipient of staff merit award from the university of Nairobi for the outstanding contribution towards the mission of the university. She was awarded elder of the burning spear by the president of Kenya in recognition of the outstanding contribution to the Nation in the field of health. She is a recipient of Malaria Afya award for contribution towards control of malaria in Kenya. Has widely published in peer reviewed journals and presented papers in numerous conferences. Her research interests are in the field of tropical disease and HIV.

Update on Visceral Leishmaniasis ( Kala-azar)Visceral Leishmaniasis(VL) is a protozoal infection transmitted by Sand flies ( phlebotomus sp). The disease is characterized by high fever, weight loss, hepato Splenomegaly and Bone Marrow suppression. It is the second largest parasitic killer after Malaria.500,000 visceral leishmania cases occur annually and 90% are from India, Brazil and Sudan.Visceral Leishmaniasis is recognized as one of the neglected tropical diseases. It is endemic in the East African region. In Kenya new foci of the disease have come up. In 2003 Leishmania East African Platform (LEAP) was created which serves as a base for training and evaluation of new treatment. Sodium Stibogluconate (SSG) for 28 days has been the main stay of treatment of VL since 1940. A short course of SSG and Paramomycine(PM) for 17days was evaluated and is now the first line treatment in the East African region. The other drugs are liposomal Amphotericine B and Miltefosine the first highly active oral drug for VL.Diagnosis of VL has been by demonstration of parasites in the bone marrow, splenic aspirate and lymph glands. Serological tests are also available. More recently a rapid diagnostic test K39 dipstick has been recommended in endemic areas where facilities are limited.Work on development is also going on but there is no vaccine yet.

Prof. K Bhatt

Short CV for Kirana Bhatt, EBS

Was born in Kenya and is a professor of internal medicine in the department of clinical medicine and therapeutics of the university of Nairobi. She did her masters in internal medicine from the University of Nairobi and specialized in tropical medicine from London school of Hygiene and Tropical Medicine. She did her training in bio Ethics from University of Washington. Currently she is the chair of National Bioethics committee of Kenya. She has also been a member of ethics committee of Kenya Medical Research institute and chair of ethics and research committee of university of Nairobi. She has been a council member of National council of science and technology of Kenya. She is a member of scientific advisory committee of Drugs for Neglected Diseases Initiative. Has been a recipient of staff merit award from the university of Nairobi for the outstanding contribution towards the mission of the university. She was awarded elder of the burning spear by the president of Kenya in recognition of the outstanding contribution to the Nation in the field of health. She is a recipient of Malaria Afya award for contribution towards control of malaria in Kenya. Has widely published in peer reviewed journals and presented papers in numerous conferences. Her research interests are in the field of tropical disease and HIV.

Dr. M Chakaya

Dr Chakaya Muhwa is a Consultant Chest Physician at the Mater Hospital and the Aga Khan University Hospital, Nairobi, Kenya. He is the Chief Research Officer at the Centre for Respiratory Diseases-Kenya Medical Research Institute (KEMRI).He is also the Chair for the Strategic and Technical Advisory Group, TB -WHO, the DOTS Expansion Working Group of the Stop TB Partnership and Technical advisor for the Kenya Association for the Prevention of TB & Lung Disease (KAPTLD). Dr Chakaya has published over 20 articles in peer reviewed journals. His research interests focus on TB, Asthma epidemiology and non TB lung infections.

Dr. Madhusudan R. Jaju, Incharge of Medical Intensive Care, Care Hospital, Nampally, Hyderabad Telangana. Internship: Government Medical College, Aurangabad – 2000Post-Graduation: K. E. M Hospital, Mumbai – 2004, Critical Care Medicine: NIZAMS Institute of Medical Sciences – 2009. EDIC: Vienna, Austria – 2013. Consultant & Incharge of Critical Care Medicine at CARE Hospitals, Hyderabad Senior Resident at NIZAMS Institute of Medical Sciences. Executive member of ISCIM, Hyderabad ChapterOrganising Committee member SZCEC-2016, Hyderabad Chairman of Highlight SessionsInfection Control Committee member. Dr. R Jaju

New paradigm in the treatment of tuberculosis

Use of immunodulators in Sepsis and Severe Sepsis


Dr. Jennifer Verani MD, MPH leads the Global Disease Detection, Epidemiology and Surveillance Program for the US Centers for Disease Control and Prevention in Kenya. She is a pediatrician, epidemiologist, and a Captain in the United States Public Health Service. She obtained her medical degree from Harvard Medical School, MPH in International Health from the Harvard School of Public Health, and undergraduate degree in International Development from Brown University. Dr. Verani completed her residency training at the Children’s Hospital of New York-Columbia, where she served in the community pediatrics track. Prior to her career in medicine, Dr. Verani worked for several years on public health programs in Latin America. In 2006 Dr. Verani came to CDC as an Epidemic Intelligence Service (EIS) officer in the Parasitic Diseases Branch, where she conducted research on schistosomiasis, lymphatic filariasis, soil-transmitted helminths, guinea worm, Chagas disease, and Acanthamoeba. Following EIS, she joined the Respiratory Diseases Branch to work on the prevention of pneumonia and neonatal sepsis. In that position Dr. Verani collaborated on studies of the effectiveness and impact of vaccines against Streptococcus pneumoniae and Haemophilus influenzae type B in several countries in Latin America and Africa, and provided technical assistance for respiratory disease surveillance in low-resource settings. She led the revision of CDC guidelines for the prevention of neonatal group B streptococcal (GBS) disease and a multi-state investigation of the remaining burden of early-onset GBS disease in the United States. In her current position Dr. Verani leads the Population-Based Infectious Disease Surveillance platform in Kibera and Asembo, and is establishing a network of Acute Febrile Illness sentinel surveillance sites across Kenya. Dr. Verani is also an Adjunct Assistant Professor of Pediatrics at Emory University School of Medicine, where she helps to train interns who serve patients at an urban primary care clinic.

SPEAKERS PROFILES & ABSTRACTS I Session V: Neglected Infections

Dr. R Virani

Dr. C Mwachari

Dr Christina Mwachari is an Epidemiologist with a clinical microbiology and research background. She qualified as a Clinical Microbiologist in 1996 and Epidemiologist in 2009. She has over 15 years research experience in infectious disease including, HIV, TB and diarrheal diseases at the Kenya Medical Research Institute. Currently, she is working as a Senior Technical Advisor in laboratory for the University of Maryland Programs in Kenya.

Name Profile

Chinwendu Achebe

BSN, MSN, ACNP

Chinwendu Achebe is the Director of Nursing at M. P. Shah Hospital. She schooled at Colombia University of School of Nursing New York USA. She was previously a Clinical Nursing Specialist at Aga Khan University hospital. She has done 15 years of nursing experience 12 of which have been spent working in corporate America.

Chinwe has a Bachelor Degree AND Masters Degree in linguis@cs

Dr. C. Mwachari

Chris@na Mwachari is an Epidemiologist with a clinical microbiology and research background. She qualified as a Clinical Microbiologist in 1996 and Epidemiologist in 2009. She has over 15 years research experience in infec@ous disease including, HIV, TB and diarrheal diseases at the Kenya Medical Research Ins@tute. Currently, she is working as a Senior Technical Advisor in laboratory for the University of Maryland Programs in Kenya

Prof. K. M. BhaI

P r o f i l e s

Title Antibiotic Stewardship in the Private Healthcare settings: Lessons LearntAuthor: Christina Mwachari MBChB, MSC, MPH, PhDIntroduction Introduction: Antibiotic use is the major driver of antimicrobial resistance (AR) worldwide. The inappropriate use of antibiotics has fuelled the emergence of AR in resource limited settings. Antimicrobial stewardship has been demonstrated to slow down the spread of AR. This evaluation demonstrates antimicrobial stewardship experience in the private settings.Methods: Antimicrobial resistance trends were obtained from selected hospitals from the inception of antibiotic stewardship committees in 2008. Lessons learnt since the inception of AS for the rational use of antimicrobials were documented. Results: Low prevalence of MRSA despite increasing trends of resistance to Staphylococcus aureus. Increased prevalence of extended spectrum beta-lactamase producing Gram negative organisms among hospital acquired infections. There was emerging antimicrobial resistance to Carbapenems. Conclusion: Effective antimicrobial stewardship was associated with reduced hospital acquired infections, improved selection of empirical antibiotics, reduced overuse of reserved antibiotics through continuous medical education.

Prevention of pneumococcal diseases and the role of currently available vaccines.


PANELISTS PROFILES

SESSION I I DR. M LUMBADr. Mohan Lumba is a Pioneer Paediatrician in Kenya. He qualified as a doctor in 1969, specialized in paediatrics in 1972 and received his Doctorate in Medicine, M.D. Paediatrics in 1974. He joined the University of Nairobi Medical School as a lecturer 1975 and has been actively involved in teaching and training paediatricians. He is an external examiner for both undergraduate and postgraduate paediatric students at the University. He has published widely in peer review jounals and has attended and participated in numerous international conferences and symposiums covering over 18 countries. He is the Chair of the Kenya Paediatric Association (KPA). He is also the Chairman of the National Influenza Taskforce and is the immediate past Chairman of the Kenya Association for the Prevention of Tuberculosis and Lung Disease.

Vice President Pan Africa Thoracic Society.Medical Practice for over 45 years.Respiratory Medicine and Infectious diseases/HIV Medicine.Patron: Kenya Lung Association.Patron: Kenya Association of Physician.Chairman: HIV Clinicians Society of Kenya.Past Chairman of several medical associations and societies.Overseas Representative - Royal College of Physicians of Edinburgh.President The Nairobi Club

SESSION V I DR. J OLUOCH


PANELISTS PROFILES

Prof Godfrey Lule currently works as professor of medicine in the Department of clinical medicine and therapeutics, University of Nairobi medical school and he is a practicing consultant Physician, gastroenterologist and thematic head of the infectious disease unit, Kenyatta National hospital. He is an adjunct professor of infectious diseases, University of Texas Medical Branch,Galveston since 2010 and University of Maryland, Baltimore since 2013. He runs a part time private practice at the Nairobi hospital as a consultant physician, gastroenterologist and infectious disease specialist.

His main area of interest has been hepatitis and HIV. He has written over 60 original research papers in various journals in addition to editing a textbook on Colonic Disorders and is author to several chapters in a few other textbooks.

SESSION IV I PROF G LULE (FRCP E)

Dr. Adam received a Doctor of Medicine degree from the University of Illinois followed by training in internal medicine and infectious diseases at the University of Arizona followed by molecular parasitology training at the National Institutes of Health. He joined the faculty of the University of Arizona College of Medicine where he worked as a Professor of Infectious Diseases and Microbiology / Immunology until 2011. He was a Fulbright scholar at the University of Nairobi in 2011 and then joined the AKUHN faculty in April 2012 as a Professor of Pathology in clinical microbiology. He is currently leading the effort to expand molecular diagnosis at AKUHN and is chair of the research committee and the infection control committee. He has been involved in numerous basic and clinical research related projects primarily in molecular parasitology and fungal infections.

SESSION II I PROF R ADAM


Prof Gunturu Revathi is Associate Professor of Microbiology at the Aga Khan University Hospital, Nairobi. She is also a visiting faculty at the University of Nairobi and the Jomo Kenyatta University of Science and Technology. She has 25 years of professional experience having worked in the Cytology Research Center at the Maulana Azad Medical College, New Delhi, Dept. of Microbiology, the University College of Medical Sciences, New Delhi before moving to Kenya. She headed the department of laboratory medicine at the Kenyatta National Hospital for 5 years while being a faculty member of the Department of Medical Microbiology at the College of Health Sciences, Nairobi .She is a visiting scientist at the Kenya Medical Research Institute where she was co-investigator in 3 research projects. Prof Revathi has supervised 45 post graduate dissertation projects throughout her career and published 60 papers in peer reviewed journals. She is a member of several national and international professional bodies such as ISID, ESCMID, ERS, KACP, APECSA, GARP and KMA. She is also on various National committees such as KAPTLD, Technical advisory committee for National Program for Tuberculosis and Leprosy, National committee on Infection prevention and control, Kenya National committee on Infectious and Parasitic Diseases Research Program (IPDRPC), Member of National working group for Clinical Management and Referral guidelines of Ministry of Medical services, Republic of Kenya.

SESSION III I PROF G REVATHI

Dr Saha (MD, MRCP) is a senior lecturer in medicine at Aga Khan Hospital, Nairobi.

He has a large ecperience in Internal Medicine and runs an actve practice in Nairobi for over25 years.

His main areas of interest are noninvasive cardiology, gustroentology and intensive care medicine.

PANELISTS PROFILES

SESSION V I DR. H SAHA


SESSION III I DR. A K SHAHFellow of the International College of Surgeons.Honorary fellow of the Society of Eye Surgeons and the International Eye Foundation.Fellow of Eastern Africa College of Ophthalmologists.Member of the Executive Council of the Ophthalmological Society of East Africa.Conferred with the Honour of Moran of the order of the Burning Spear (MBS).Member of the Board of Governors of The Social Service League and MP Shah Hospital.Divisional Surgeon of The St. John Ambulance Brigade.Technical Advisor for the Sightfirst programme - Africa region.Member of the National Prevention of Blindness Committee of the Ministry of Health, Government of Kenya.

Professional training: Post-graduate Diploma in Paediatric Infectious Diseases, University of Oxford 2014, MSc Paediatrics and Childhealth, University of Nairobi 1985. Practice: Private practice in Nairobi.Appointments: Consultant for HIV services in Gertrude’s Garden Children’s Hospital. Honorary lecturer department of Paediatrics and Childhealth, University of Nairobi.Member of: National Technical Working Group NASCOP, for development of National HIV guidelines and management of ART 2nd line failure casesTWG Kenya Essential Medicines List 2016.National Polio Experts Committee for Kenya and SomaliaCurrent Research activity: Site PI Gertrudes Hospital for LIVING study (Lopinavir sprinkles)

SESSION I I DR. J MBUTHIA

PANELISTS PROFILES


Dr. Dhirane Shah qualified in Internal Medicine from M.P. Shah Medical college, 1990.Currently a consultant physician practicing as a hospital physician at The M.P. Shah Hospitaland a private practitioner at both The M.P Shah Hospital and The Aga Khan University Hospital.He has a special interest in Cardiology.

Dr. S. T. Patel

Dr. J. M. Chakaya

Dr. M. Jivanjee

Dr Surendra Patel is the event organizing chair and MC. He is an internationally trained physician with an established private practice in Kenya.He is currently Adjunct Professor at the University Of Nairobi. He was amongst the first physician to diagnose and treat HIV & AIDS in Kenya. He has experience and diagnosis treatment of HIV & AIDs patient in Kenya. He has collaborated with local and international research projects in his field of HIV & AIDs and was involved in a landmark study which facilitated availability of anti retroviral drugs in both public and private sectors in Kenya.He is also a member of various Local and International Policy making bodies in the field of HIV & AIDs.

Dr Chakaya Muhwa is a Consultant Chest Physician at the Mater Hospital and the Aga Khan University Hospital, Nairobi, Kenya. He is the Chief Research Officer at the Centre for Respiratory Diseases-Kenya Medical Research Institute (KEMRI).He is also the Chair for the Strategic and Technical Advisory Group, TB -WHO, the DOTS Expansion Working Group of the Stop TB Partnership and Technical advisor for the Kenya Association for the Prevention of TB & Lung Disease (KAPTLD). Dr Chakaya has published over 20 articles in peer reviewed journals. His research interests focus on TB, Asthma epidemiology and non TB lung infections.

Dr. Jivanjee is working as the Resident Surgeon at M.P Shah Hospital. He completed his MMed in General Surgery at the University of Nairobi in February 2012, and Fellowship in General Surgery (COSECSA) in December 2013. His interests include Laparascopic and Hepatobiliary Surgery.

PROFILES

Dr. Dhirane Shah

Dr. Dhirane Shah qualified in Internal Medicine from M.P. Shah Medical college, 1990.Currently a consultant physician practicing as a hospital physician at The M.P. Shah Hospital and a private practitioner at both The M.P Shah Hospital and The Aga Khan University Hospital.He has a special interest in Cardiology.

Dr. Enoch Omonge

Dr. Omonge is qualified in MBChb (Nairobi) and MMed (Nairobi)He is a leading authority in clinical therapeutics and pharmacology.He has an interest in HIV medicine and a respected member of the faculty at the University of Nairobi.He is the general secretary of society of AIDS in Africa and the Kenya HIV Clinicians AssociationHe has authored numerous research articles in the field of HIV and Diabetes.

C

M

Y

CM

MY

CY

CMY

K

Symposium programme 2.pdf 3 18/07/2014 10:23:58

SESSION II I DHIRANE

Consultant Physician and Cardiologist, head of cardiology MP Shah Hospital, Nairobi Kenya. Consultant Physician and Cardiologist at the Forces Memorial Hospital Nairobi Kenya. Consultant Physician Equator Meridian Hospital Nairobi. Consultant physician naval hospital, Mombasa. Part-time/locum physician at the Agha Khan University hospital Nairobi, Pandya and Mombasa hospitals in Mombasa. Visiting Physician of the AMREF flying doctor services. Senior House Officer in the department of Internal Medicine, University of Nairobi at the Kenyatta National Hospital. Senior Medical Officer at the Nyali Barracks in Mombasa. Medical officer in the Ministry of Health at Kitale District Hospital. Internship training at the Moi Refferal and Teaching Hospital Eldoret.

SESSION IV I DR. B SAMIA

PANELISTS PROFILES


Suryakalaben Maganlal Chandaria Children’s Medical Centre M. P. Shah Hospital has set up a brand new state of the art Children’s Hospital in Nairobi. The new ‘Suryakalaben Maganlal Chandaria Children’s Medical Centre’ is an ultramodern facility offering critical care inpatient and out-patient services for children. The unique 5 story children’s hospital has 30 rooms specially designed to meet the needs of the patients, the family and the caregiver and at any point of time it can accommodate up to 50 inpatients. All medical supplies are built into the wall behind the patient to allow for sophisticated bedside technology. Each has got attached bathroom with all modern amenities. The rooms in each floor are designed in a way to take care of children below two years and above. The Paediatric Intensive Care Unit (PICU) / NeonatalIntensive Care Unit (NICU) and Paediatric High Dependence Unit (HDU) are staffed by highly trained doctors and nurses who specialize in caring for critically ill patients. This ICU has a higher staff-to-patient ratio and access to advanced medical resources. Common conditions that are treated within this ICU include- Acute respiratory distress syndrome, trauma, multiple organ failure and sepsis. Patients may be transferred directly to an intensivecare unit from an emergency department if required, or from a ward if they rapidly deteriorate, or immediatelyafter surgery if the surgery is very invasive and the patient is at high risk of complications. The new ICU is equipped with the latest emergency response monitors, defibrillators, ventilators etc. Each patient has a bedside and centralized cardiac monitoring system. The new ICU beds are designed to keep patients both safe and comfortable. Each room is very spacious with full glass walls, all the equipment are wall mounted so as to keep the floor clean and infection free.The following services are currently offered at the Suryakalaben Maganlal Chandaria Children’s Medical Centre:

1. Well Baby Clinic 6. Children’s Sub Specialty clinics2. Vaccination Centre 7. Pediatric Intensive Care Unit3. Neonatal Intensive Care Unit 8. Pediatric High Dependency Unit4. Dedicated pediatric pharmacy 9. Diagnostics – Pathology Lab & Radiology Services5. In patient rooms for Children-dedicated below 2 years & above

M. P. SHAH HOSPITAL


The New Dr. Kanubhai Babla Intensive Care UnitThe M. P. Shah Hospital’s Dr. Kanubhai Babla Intensive Care Unit (ICU) is located on the ground floor of the Dr. Kanubhai Babla Medical Centre. It is a specially designed 7 bed rooms (of which 2 are isolation rooms with negative pressures) that deals with patients with high risk for actual or potential life threatening health problems. Working in ICU requires a lot of focus and stamina but very satisfying. Dealing with critically ill patients requires continuous monitoring of every detail of the patient’s hemodynamic parameters, physiological processes like voiding and breathing to their medication and interacting with their relatives and keeping themup to date and reassured at all times. Empathizing with their relatives and understanding the constant worriesand anxiety concerning the patients and giving them all the available options. Being there for the critically ill and helping them overcome the stress related to disease responses, pain free and still maintaining their dignity and decency. Because of the delicate balance of the critically ill patients, the care delivered must include collaboration of all the other discipline involved in care of consistent approach based on knowledge and skill. They include physicians, critical care nurses, anesthetists, physiotherapist, pharmacists, nutritionists and pathologists. Although critical care unit is a very stressful place, staffs help each other in stress coping mechanisms that make it remain the most satisfying department to work in!

M. P. SHAH HOSPITAL

Professional Services In All Spheres Of Healthcare

We would like to congratulate NHIF on this 50 year celebration and are proud to be associated with this esteemed institution for so many years, we are also proud that we are one of the most preferred partners in the private sector and are able to provide high quality of care at affordable costs. We are a Social Service League, not for profit organization in existence for last 83 years and these are very exciting times indeed for the M. P. Shah Hospital. We are on a transformational expansion phase for last few years and were able to build up capacity from a 90-bed to become a multi super-specialty, state-of-the art, tertiary care hospital with 210 fully functional & operational beds, 30 dedicated critical care (ICU/HDU/CCU/NICU) beds, 10 renal dialysis units and 12 chemotherapy units in 2016, 4 Modern Theaters, Cardiac Center, Cathlab, dedicated Maternity center, Children’s hospital and is set to grow to a total of 300 beds by the end of 2017.We welcome you to come and see the new infrastructure of M.P. Shah Hospital and witness the change in providing world class healthcare, infrastructure and services.

Please visit the following new developments in this hospital:-

New State of the art Children’s hospital with its own 24 hours casualty, Well-baby center, Sub Specialty clinics, NICU, PICU & PHDU.New State of the art, most modern Intensive Care Unit and High Dependency Unit set up in the region, at the ground floor of Dr. Kanubhai Babla Medical Center.New cardiac center with specialized cardiac diagnostics and state of the art Cath Lab doing all kinds of interventional cardiac procedures.New executive and private rooms at the 2nd and 3rd floor of Dr. Kanubhai Babla Medical Center.New Laminar floor theatre at the 1st floor of Dr. Kanubhai Babla Medical Center.New 3 Tesla MRI, 128 Slice Cardiac CT Scan, digital X Ray, Mammography, 4D Ultrasounds and OPG units in the radiology center.Automated hematology analyzer, New fully automated Biochemistry equipment, Fully Automated microbiology unit & automated Histopathology units in the Pathology Lab.

Brand new dental center with maxillofacial and orthodontic specialties.Brand new ENT center with all modern equipment and Audiology Unit.A modern wound management clinic and trauma center at the Accident and Emergency unit.Renal center with advanced Dialysis units, CRRT machines and Kidney transplant unit.We do all kind of Orthopedic implants, replacement surgeries, Neuro & Spine proceduresOur Maternity center gives birth to on an average 150 babies every month.Our Accident & Emergency unit receives around 6000 patients every month.We perform around 5000 different kinds of lab tests available in this world.We have state of the art oncology management unit with Chemotherapy, Oncology surgeries, in patient management & Palliative care.We have 3 Tesla MRI, 128 Slice CT Scan, 4D Ultrasounds, digital Mammography, X-Ray & OPG

Congratulations!!

Congratulations!!

Cathlab MRI ICU Executive Room

Grand EntranceWell Baby ClinicKanubhai Babla Medical CentreSuryakala Children’s Medical Centre

www.mpshahhosp.org I [email protected] I (020) 4291000 / 0733606752 / 0722204427 / 0733606113 / 0722783350

M. P. SHAH HOSPITAL


M. P. SHAH HOSPITALCardiology Unit and Cath LabM.P Shah Hospital has invested in a Cardiology unit with a modern state-of-the-art catheterization laboratory (Cath-Lab) which is located on the 4th floor of the Dr. Kanubhai Babla Medical Centre. The Cath Lab is fitted with high end diagnostic imaging equipment. The M.P Shah Hospital Cath lab is staffed by a multidisciplinary team who are able to conduct the following procedures:-

• Coronary Angiography or Coronary catheterization• Coronary Angioplasty or Percutaneous coronary• Intervention / PCI• Closure of some congenital heart defect• Treatment of stenotic heart valves• Permanent and temporary pacemaker implantations• Electrophysiological studies such as AV node• Ablation• Rot ablation of heavily Calcified vessels• Left and right Sided pressure studies

The cardiac clinic is a state of the art facility offering all forms of diagnostic, therapeutic and intervention services related to cardiovascular and metabolic diseases. It prides of bringing in the latest unparalleled technology in management of cardiovascular diseases.The clinic offers the following services:

• Full time cardiology consultations• ECG services • Holter monitor services • Ambulatory BP monitor services • State of the art Echocardiography with 4D application, both transthoracic and transesophageal.

Portable echo services for ICU, wards, theatre are also done. • Stress Test services, via Stress or Pharmacological modes


A brand new dental CentreM.P Shah Hospital has set up a brand new dental centre with the aim of incorporating the best new dental technology into the state of the art practice, making it one of the most advanced centers in the country. This new cutting edge technology includes:• An internationally recognized maxillofacial Surgeon

who specializes in treating diseases, injuries and defects in the face, jaws, hard and soft tissues of the Oral (mouth) and Maxillofacial (jaws and face) region.

• An internationally recognized orthodontic surgeon who has specialized in preventing, diagnosing and treating dental irregularities.

• 2 General DentistM.P. Shah dental centre is excelling in the field of Dentistry every year for more than a decade now. Here we believe newer techniques, technology and our perseverance bring us close to perfection in our work. Our centre provides the finest Dental Services with state-of-the-art equipments, you name it we have it!!This is a place where each one of us believes Dentistry is our passion and patient care is our utmost concern. Wonder why we are different from the rest of the others! There is just one difference: Our expertise guarantees that you leave with a healthier, more beautiful smile. Our wide range of dental treatments, tailored to both Children and Adults, includes all types braces treatment like aesthetic braces, invisible braces (lingual) , invisalign ( clear aligners), self ligation braces treatment, functional appliance and orthopedic treatment. Wide range of maxillofacial surgery like trauma, cancer surgeries. Orthognathic ( cosmetic face surgery), TMJ problems . treatment of snoring and obstructive sleep apnoea, Single Sitting RCTs, periodontal Laser therapy, Smile enhancements, Teeth Whitening, Dental Implants, Metal free, Aesthetic crowns, bridges and Veneers, being our Speciality.

CONSULTANT ORAL & MAXILLOFACIAL SURGEON

AND HEAD OF DENTAL DEPARTMENT

Dr. Shalender Sharma

He joined M. P. Shah Hospital

as a Consultant Oral and

Maxillofacial Surgeon on 1st

June 2016. Dr. Shalender

holds a Bachelor degree

in Dentistry (B.D.S) from

Kurukshetra University,

M.M Dental College, Ambala, Haryana and Masters

in Dentistry (M.D.S) from Tamilnadu University,

Ragas Dental College, Chennai among several other

professional certifications.

He has over 11 years of experience in Dentistry, Oral

& Maxillofacial Surgery. Prior to his appointment,

he was working as a Specialist Maxillofacial Surgeon

in Botswana. He has previously worked as a Senior

lecturer in M.M Dental College, Ambala, Haryana &

Teerthanker Dental College in Moradabad, India. He

also worked as Associate Professor in the Department

of Oral and Maxillofacial Surgery in STG Dental College,

Gurgaon, India.

He is a Specialist in Maxillofacial trauma, dental

implants, maxillofacial pathology(oral cancer), cleft

lip and palate, orthognathic surgery, T.M.J disorders

among other procedures. Dr. Shalender has 21

publications 15 of which are national and 6 that are

international. He is a member of the Association of

Oral and Maxillofacial Surgeons of India (AOMSI) and

member of the Indian Dental Association.

M. P. SHAH HOSPITAL


M. P. SHAH HOSPITALCONSULTANT ORTHODONTIST

Dr. Kaberi Majumder

She joined M. P. Shah Hospital as a Consultant

Orthodontist on 1st June

2016. Dr. Kaberi holds a

Bachelor degree in Dentistry

(B.D.S) from Rajuv Gandi

University of Health Sciences

India and Masters in Dentistry

(M.D.S) from The Tamilnadu,

Dr. MGR Medical University

among several other professional certifications.

She has has over 11 years of experience in Dentistry

and Orthodontics. Prior to her appointment, she was

a Reader in Dashmesh Institute of Dental Science,

Faridkot. She also previously worked as a Senior

Lecturer in SGT Dental College and Teerthanker

Mahaveer Dental College. She has also practiced as a

Consultant Orthodontist at the Max Hospital in New

Delhi and Park Hospital in Gurgaon.

Dr. Kaberi has 15 publications 8 of which are national

and 7 that are international. She is a member of the

review board of the Indian Journal of Dental Science

and Research and a Co-Editor of the Dental Showcase

bulletin by Teerthanker Dental College.


M. P. SHAH HOSPITAL

Executive Pavilions and VIP roomsAt M.P. Shah Hospital, we understand some patients desire an additional level of luxury and comfort during their hospital stay. The Hospital has recently opened Executive and V.I.P rooms at the 2nd and 3rd Floors of Kanubhai Babla Medical Centre, allowing patients and their families to experience a level of customized service and comfort in a relaxing and private environment. The rooms combine the comfort of knowing you have chosen the best possible medical facility with a touch of luxury to enhance quick recovery.


Wound Management ClinicM. P. Shah Hospital now has a Wound Care Center which is one of its kind in the region. The M. P. Shah Hospital Wound Care Center was inaugurated on 13th may 2016 by Prof. Khainga.MP Shah Hospital is the first hospital to have this high standard facility in the country. The department is located in the accident and emergency department. It is equipped with high quality dressing materials, suitable for all kinds of wounds. The unit is headed by the nurse in charge who coordinates the operation of the unit.Dressings are done on appointment basis to enhance proper and early preparations for the patients and materials to be used. A schedule is in place to accommodate the patients’ needs to enhance patient delight. Dressing of the wounds is done by the specialty nurses in A&E in collaboration with the A&E doctors and in constant consultation with the surgeons where need arises.The materials we use are as follows; 1. For debridement – intrasite gel for autolytic debridement, iruxol for conservative sharp enzymes, and adsorb for chemical debridement and versa jet for surgical debridement. 2. For bacterial balance – acticoat, allevyn and bactigrass 3. For inflammation reduction – monocrystalline silver which helps reduce the bacterial load in the wound which is causative of prolonged inflammation 4. For moisture maintenance – elect foam, allevyn, and opsite flexi grid and opsite post –op.This maintains the appropriate moisture levels to help facilitate healing 5. For advance closure – opsite flexigrid and secura.We look at at our patients comprehensively by identifying the factors that delay proper wound healing for example their nutritional status, any underlying medical conditions e.g. cancer or diabetics, age, cause of the wound, compliance to antibiotics and other medications, environment and materials used for dressing. In view of all this, we give our patients a detailed health education based on assessment and identified individual problems. We not only address patient wounds but also give psychosocial support to enable a holistic approach to the healing process.

M. P. SHAH HOSPITAL


Magnetom Spectra 3Tesla MRI Equipment from SiemensThe Hospital is acquiring a state of the art, sophisticated; most advanced Magnetom Spectra 3Tesla MRI Equipment from Siemens in the 2nd week of August. This MRI is going to be the best in the region, designed with patients’ comfort in mind, while incorporating image quality, this MRI will boost the Radiology Department tremendously. The MRI will improve the quality of patient care leading to faster and more accurate diagnoses and more specific treatment of medical conditions. The system offers unprecedented access to 3 Tesla Magnetic resonance imaging. It is the key to a new scope of image and diagnostic confidence for physicians. This will be the first machine with such technology of its kind in Africa.

M. P. SHAH HOSPITAL


Jamal Devji Family ENT CentreIn order to remain consistent in providing quality healthcare the Hospital is in the process of acquiring a state of the art ultramodern Ear, Nose and Throat / Head and Neck Clinic to provide the much needed services to its patients. The centre will be providing diagnosis, evaluation and treatment of both common and highly complex ENT disorders, as well as diseases affecting the head and neck. The centre will be run by a professional team of doctors and nurses dedicated towards offering the latest treatment options to patients.

· General ENT examinations· Endoscopic examinations: Nasal endoscopy, video-otoscopy and Laryngoscopy· Videostroboscopy and voice management · Pure Tone Audiometry and Tympanometry· Hearing AID fitting and dispensing· Nystagmograhy and vestibular rehabilitation· Microscopy· Ear Syringing· Basic minor surgical procedures· Sleep studies

Quadruple endoscopy centre with 4 light

outlets, each 150 W halogen or LED light, light

barrier controlled lighting, automatic

activation of head light, preheating quivers,

disinfection quivers, disinfection time control,

quivers for flexible scopes

All handpieces and applied parts are fully

autoclavable (water handle, spray handle, spray

cannulas, nozzles etc.). Quick-fit

couplings on all hoses ensure easy assembly

To enlarge the workspace, a swivel support

is available to integrate a stroboscope,

ultrasound unit etc.

Details

Dispenser for examination gloves

or Kleenex tissues

Compartment with examination gloves

dispenser

Dispensers for cotton wool and tongue

holder tissues

Paper dispenser for instrument surface.

Even without a helping hand a clean

instrument surface is ready for the next patient

in seconds














Details


or Kleenex tissues


dispenser


holder tissues




in seconds














Details


or Kleenex tissues


dispenser


holder tissues




in seconds

M. P. SHAH HOSPITAL




MATERNITY CENTRE

ANTENATAL BOOKINGAND MATERNITY EDUCATION

We provide a range of education programs to inform and empower you as you approach the birth of your baby.

PACKAGES

Pregnancy Choices of Maternity Care

M.P. Shah Hospital acknowledges that pregnancy is an exciting time for women and their families and offers a range of services to meet your individual needs.

At M. P. Shah Hospital, you have a variety of choices of maternity care available to you.

Your choice will depend on:• Your wishes• Issues that arose in a previous pregnancy

• Any medical conditions that you now have• Conditions that may arise in this pregnancy• Where you reside.

Your choices include:• Hospital Doctor based care• Midwifery care• Private obstetric care.


Packages

Non stress testCSSD and DrugsPediatrician’s chargesBaby billsReceiving of babyPhysio

2 days admissionSterlization chargesNursing chargesDoctor delivery chargesDoctor’s visitLabor room chargesDelivery Charges

5 days admission Sterlization chargesNursing charges Doctors visitSurgeon’s fees Anaesthetic chargesTheatre pack CSSD and Drugs OT charges Pediatrician charges

Normal delivery supervised by Doctor

NB: To qualify for the package, the full package amount must be paid upfront before 30 weeks gestation

EMERGENCY CEASERIAN IS NOT COVERED WITH THIS PACKAGE THE FULL BILL IS PAYABLE BY THE PATIENT

Please note mothers sanitary pack is charged extra over and above the package price, baby items pack is also available with additional charge

Please note mothers sanitary pack is charged extra over and above the package price, baby items pack is also available with additional charge

Caesarean sectionReceiving babyBaby billsNon stress testPhysio

210,000/=

95,000/=

.......................................................................


PLEASE NOTE THAT YOU MUST SUBMIT YOUR NHIF CARD OR PAY CASH

Admission more than 2 days bills for NORMAL DELIVERY to be paid in full from the 3rd day.

Admission more than 5 days bills for CAESAREAN SECTION to be paid in full from the 6th day.

Vacuum, complicated delivery, twins/breech delivery or instruments used for delivery are an additional charge of

27,000/=

PLEASE NOTE THE PACKAGE MAY CHANGE ACCORDING TO THE TYPE OF DELIVERY AND THE OUTCOME. YOU MAY BE REQUIRED TO PAY

ACCORDING TO THE PACKAGE YOU FALL IN AT THE TIME OF DELIVERY.ANY INVESTIGATIONS e.g. ULTRA SOUND, BLOOD GASES FOR ANTENATAL

PROFILE ETC. WILL BE CHARGED SEPERATELY.RESACITATION OF NEWBORN WILL ATTRACT ADDITIONAL CHARGES.

NO REFUNDS ARE GIVEN AS THIS IS A PACKAGE PRICE

Flexible solutions for Your maternal needs,

Comfortable and Affordable accommodation

For you and your child

: DL: :020 4291621 / 020 4291622 / 020 42910629 / 020 4291000 0722 783 350 / 0733 606 752 / 0733 606 113

[email protected] / [email protected]. Shah Hospital @MPShahhospital

www.mpshahhosp.org

IMPORTANT NOTICE



Pulling patients fromthe depths of serious infection

Meronem™ IV (Injection). Meronem IV injection contains meropenem 500 mg or 1 g as the trihydrate blended with anhydrous sodium carbonate for constitution. Each gram of meropenem (anhydrous potency) contains 208 mg sodium carbonate. PHARMACEUTICAL FORM: Sterile white powder for solution for intravenous injection of infusion. THERAPEUTIC INDICATIONS: Treatment, in adults and children, of the following infections caused by single or multiple bacteria sensitive to meropenem: Pneumonias and Nosocomial Pneumonias, Urinary Tract Infections, Intra-abdominal Infections, Gynaecological Infections, such as endometritis and pelvic inflammatory disease, Skin and Skin Structure Infections, Meningitis, Septicaemia, Empiric treatment, for presumed infections in adult patients with febrile neutropenia, used as monotherapy or in combination with anti-viral or anti-fungal agents. Meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. For full prescribing information refer to the package insert approved by the medicines regulatory authority. AstraZeneca Pharmaceuticals (Pty) Ltd. Reg. No. 1992/005854/07. Building 2, Northdowns Office Park, 17 Georgian Crescent West, Bryanston, 2191. Private Bag X23, Bryanston, 2021, South Africa. Tel: +27 (0)11 797-6000. Fax: +27 (0)11 797-6001. www.astrazeneca.com Meronem is a trademark of the AstraZeneca Group of Companies. Expiry Date: March 2018. Activity ID: 762695.

References: 1. Unal S, Masterton R, Goossens H. Bacteraemia in Europe—antimicrobial susceptibility data from the MYSTIC surveillance programme. International Journal of Antimicrobial Agents 2004, 23:155–163. 2. Rahal JJ. The role of carbapenems in initial therapy for serious Gram-negative infections. Critical Care Medicine. 2008;12(Suppl 4):S5 (doi:10.1186/cc6821).

1

MeronemTM

optimise outcomes – every hour counts2


SPEAKERS PROFILES & ABSTRACTS I Session III: Bacterial Infections

For more than 150 years, a very special passion has driven the people of MSD. Our goal is to develop medicines, vaccines, and animal health innovations that will improve the lives of millions. Still, we know there is much more to be done. And we’re doing it, with a long-standing commitment to research and development. We’re just as committed to expanding access to healthcare and working with others who share our passion to create a healthier world. Together, we’ll meet that challenge. With all our heart.

MEDICAL BREAKTHROUGHS MAY COME OUT OF THE LAB.BUT THEY BEGIN IN THE HEART.

Copyright © 2014 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA All Rights Reserved.


NAIROBI ENTERPRISES LIMITED (NEL) was established in Nairobi in 1978. It is a limited company owned by the Dhanani family. Currently located at SAACHI PLAZA, GROUND FLOOR B-WING B1 ARGWINGS KODHEK ROAD KILIMANI PAST YAYA CENTRE.

At Nairobi Enterprises Ltd we are committed to delivering quality equipments for the region with a focus to guarantee our clientele excellent quality products and service.

Nairobi Enterprises Ltd is one of the Major distributors of medical Equipment, veterinary medicines and feeds supplements in the East and central African regions.Our aim in veterinary is to o�er quality, a�ordable products and professional services to our farmers.

NEL has the widest choice of Equipments backed by the most skilled technical back-up in the region.

NEL has been the market leader in PSA oxygen systems and dental units in the region. NEL employs 53 permanent sta� in various departments. Annual turnover is approximately 74 million dollars.

Sister companies owned by the same family include Universal Corporation Ltd and Chemoquip Ltd among others.

Our strength in the market is our ability to provide back-up service for the equipment we supply. Many of our customers are on service contracts for larger equipments such as oxygen generators, Concentrators, dental units Etc. The equipments therefore give longer life and fewer interruptions.

Our other strength is training our customers to understand as much about technical details of our equipments as possible. Whenever we undertake installation of our Equipment we want to do it with the customers representatives so that the customer is familiar with the equipment.

During the last decade NEL has taken consistent steps to add value to relevant products and innovative solutions. Nairobi Enterprises Ltd meets quality benchmarks and retains cost e�ectiveness to compete with the best in the world.

Our huge product portfolio includes; Oxygen generators and concentrators, Dental units, Hospital furniture, Anaesthesia machines, Autoclaves and sterilizers, Baby Incubators, BP Machines, Diagnostics, Disposables and dressing, Surgical Instruments, Hollow ware, Ultra sound scanners, Doppler’s, Patient Monitors, Diathermy Machines, ECG machines, Nebulizers, suction Machines, Orthopedic implants and items, Pulse Oximeters, scales instrument sets, Sutures, Theatre, Packaging Materials required in Medical Fraternity among many others.

NAIROBI ENTERPRISES LIMITED also o�ers Equipments on Rental Basis and hire purchase subject to set terms and conditions.

NAIROBI ENTERPRISES LIMITED Mission is to provide a�ordable good quality medical equipments while its vision is to be the medical equipments provider of choice within the East and central African region and beyond.Nairobi enterprises Ltd is therefore your one stop medical shop for all you medical items requirements and Pharmaceuticals. We are authorized distributor of Fresenius Kabi Oncology Ltd formely Dabur Pharma Ltd India, Bharat Serum and Vaccines Ltd, Airsep, Gnatus products.

NELNairobi Enterprises Limited

Glenmark Pharmaceuticals Key Products

Glevonix 500 mg Tablets / IVLizolid 600 mg Tabs / IV

Esose 20 mg / 40 mgFlexilor P / P8

ZupricinMomateIbicar s

CanditralSaferon Syrup / Tablets

Ketoplus

Since 1948 Denk Pharma products are … Registered Manufactured Quality controlled

… in Germany! Analgesics

Antiallergics Anti-infectives Antimalarials Cardiovascular drugs Dermatologic drugs

Food Supplements Gastro intestinal drugs Metabolic drugs Minerals & Vitamins Oncology Respiratory drugs

Our therapeutic areas:

Contact us: www.denkpharma.de Distributors: Laborex ltd, Omaera Ltd, and Symbio Ltd

Quality and a�ordable branded genericsAvailable to our patients;

1. ANDARAN 150MG 30FCT EAC (IRBESARTAN)2. ANDARAN 300MG 30FCT EAC3. ANDARAN 75MG 30FCT EAC4. ANDARAN HCT 150+12.5MG 28FCT EAC5. ANDARAN HCT 300+12.5MG 28FCT EAC6. BANEOCIN 20G OINTMENT (BACITRACIN/NEOMYCIN)7. BIODROXIL 125MG 60ML POS (CEFADROXIL)8. BIODROXIL 250MG 60ML POS9. BIODROXIL 500MG 12’s10. PEROMENE 1G 10’s (MEROPENEM)11. PEROMENE 500MG 10’s12. PIP/TAZO SDZ 4G/500MG 1PSOIJ EAC (PIPERACILLIN/TAZOBACTUM)


Pro�le of GlaxoSmithKline Pharmaceutical Kenya Limited

GlaxoSmithKline (GSK) is one of the world’s leading research-based pharmaceutical and healthcare companies. We have a challenging and inspiring mission to improve the quality of human life by enabling people to do more, feel better and live longer. The company is headquartered in the UK with major business operations in the US and employs 99,000 people in 120 countries.In East Africa the company started operations in 1956, then as Burroughs Wellcome. The headquarters for the East Africa business is based in Nairobi, serving key countries in East Africa for example Ethiopia, Djibouti, Uganda, Rwanda, Tanzania and Kenya.GSK’s business in East Africa is unique, as our manufacturing site, consumer healthcare and pharmaceutical operations are all based at our Likoni Road facility in Nairobi. The company has a workforce of 323 people in the region.

On 2nd March, GSK (globally) announced it concluded its three-part transaction with Novartis involving our Consumer Healthcare, Vaccines and Oncology businesses:

• GSK and Novartis have combined their consumer healthcare and over-the-counter (OTC) businesses, respectively, to form a new company, called GSK Consumer Healthcare • GSK has acquired Novartis’ global Vaccines business, excluding in�uenza vaccines (except in China, where GSK bought Novartis’ �u business) • Novartis acquired GSK’s marketed Oncology portfolio and associated R&D activities.

The transaction has enabled GSK to substantially strengthen two of its core businesses – Vaccines and Consumer Healthcare – through scale and focus, release further value to shareholders and delivering far-reaching bene�ts to patients and consumers.

In view of the transaction, a new trading entity called GlaxoSmithKline Pharmaceutical Kenya Limited was created. GSK business in Kenya and East Africa as at 1st July 2015 separated such that the Pharmaceutical business now trades under GlaxoSmithKline Pharmaceutical Kenya Limited while the Consumer Healthcare and Manufacturing business continues to trade under GlaxoSmithKline Limited.In connecting with our communities, the company has made a commitment to donate albendazole for the school deworming programmes in public schools and to work with the World Health Organization to eradicate lymphatic �lariasis through the albendazole donation programme by 2020. In partnership with Save the Children and Amref Health Africa, we are contributing to improving maternal health and strengthening the health system by training health care workers.


OVERVIEW

Aurobindo Pharma Limited was founded in India year 1986. The company is worth over 1 billion USD with a strong focus on R & D and globally accredited regulatory agencies approved plants.

Aurobindo o�ers a large product portfolio of over 400 products covering a wide range of therapeutic segments such as neurosciences, cardiovascular, anti-retroviral, anti-diabetics, gastroenterology and cephalosporin’s, among others.

Aurobindo is emerging stronger in Africa, Asia, Middle East, CIS and Latin America and exports to over 125 countries across the globe. The company strives hard to provide world-class quality medicines at a�ordable prices with a strong commitment towards healthier life.

On behalf of Getz Pharma, I would like to commend the M.P.Shah hospital for organizing this year’s Infectious Diseases Forum. I am sure this conference objective is to provide a platform on which the Physicians and Infectious disease specialists can share practical and local experiences in prevalence, control and treatment options for infectious Diseases.Getz Pharma has continued to partner with M.P Shah Hospital and other health providers in availing our world class Branded Generic Medicines at affordable prices and superior quality. In this regard, in 2014 Getz Pharma achieved the WHO prequalification of our quality Control laboratory at the manufacturing facility, making us the one of the 38 with such accreditation worldwide. Additionally, we are among the few companies in the region to achieve the PIC/s GMP recognition.We wish all the delegates a good learning experience during the conference.


Who we are:Pfizer Laboratories Limited is a wholly owned subsidiary of Pfizer Incorporated, New York, the world’s largest biopharmaceutical company established in 1849.History in Nigeria & East Africa Region (NEAR):Pfizer started operations in Africa in 1957 with Nairobi being the regional head office for Africa and the Middle East. It then set up a second pharmaceutical plant for the West African sub-region in 1976 at Oregun, Lagos, manufacturing, marketing and distributing Pfizer brands of Pharmaceutical and Veterinary products. The company also had manufacturing operations in Nairobi, Kenya.Pfizer NEAR Today:Today, Pfizer NEAR continues to maintain a significant presence in Nigeria, Ghana and the East African Region (NEAR Markets) that dates back to 1950s, operating with Headquarters for Pfizer (NEAR) – Nigeria, Ghana, and East Africa in Lagos. Co-ordination of medical operations in the region and marketing of other new products from Pfizer Research & Development efforts.Key Therapeutic Areas:Pfizer has significant presence in cardiovascular disease areas with its key brands such as Norvasc and Lipitor. Other disease areas where the company contributes significantly include pain and anti-infectives. With the acquisition of Wyeth by Pfizer Inc., Pfizer expanded into the new area of vaccines. The Pneumococcal Vaccine, Prevenar 13, being the first vaccine launched by Pfizer in the NEAR market is a strategic preventive intervention against pneumonia - the cause of an average of 20% deaths of children under five in Nigeria. Other top of the range brands include Viagra, Neomedrol and Depo Provera. In addition to our commercial activities in Nigeria, Pfizer has created direct employment for over one hundred people and indirect employment for another 250 people, Pfizer invests in every community where it has operations. This is in line with our core value of “Working together to make the world a healthier place”. Some of these activities include:• International Trachoma Initiative (ITI)ITI is a partnership between Pfizer and the Task Force for Global Health, which

supports the goal of eliminating blinding trachoma, the leading cause of preventable blindness, by 2020. Pfizer donates Zithromax* (an antibiotic) for the free management of trachoma, a leading cause of blindness in Nigeria. Pfizer has provided close to 225 million Zithromax* treatments totaling almost $5 billion USD for use in 19 countries. • Diflucan Partnership ProgramPfizer created the Diflucan Partnership in 2000 to improve the quality of life for people living with HIV and AIDS. Pfizer and its partners distributed millions of Diflucan (Fluconazole) treatments for two AIDS related fungal infections in Nigeria, Kenya, Tanzania and Uganda.• Infectious Diseases InstitutePfizer and other partners established the Infectious Diseases Institute (IDI) in Uganda in 2004. The IDI, a major medical training and research centre headquartered within Uganda’s Makerere University, aims to improve health in Africa by training medical professionals and providing them with skills and resources to use in their communities. Since 2004, IDI has trained more than 5,810 healthcare providers from 27 African countries. • Cardiovascular Screening ProjectThis project involves the free CV medical screening of the general public and it addresses the growing concern of cardiovascular diseases in Africa. The programmes are held in pharmacies, religious organizations and corporate establishments and in partnership with health care institutions. It covers health parameters like blood pressure, glucose and cholesterol. Pfizer conducted free screenings for over 5000 persons in 2010 and this year has screened more people.• Glaucoma ScreeningsGlaucoma is the second leading cause of preventable blindness worldwide, not because of lack of effective methods for diagnosis and treatment, but due to limited public awareness of the disease and its implications. It is asymptomatic in its early stages, while the patient's vision suffers irreversible and cumulative damage. Visual disturbances are noted by the patient at late stages on the way to blindness, whereas timely diagnosis and therapy could have prevented this degradation. The key to preventing the progression to vision loss is early detection hence Pfizer’s decision to hold free screenings as part of its Corporate Social Responsibility (CSR) activities. Working in partnership with the Federal Ministry of Health, the Ophthalmological Society of Nigeria (OSN), Nigeria Optometric Association (NOA), the Ayo Bello Foundation and several teaching hospitals, Pfizer has carried out several free glaucoma screenings pan- Nigeria.

Alkem labs Ltd was registered in Kenya in 1999. The company is amongst Top 10 (Ten) companies in India with internationally recognized brands such as CLAVAM, PAN 40 and ENZOFLAM among others.It has international approvals from USFDA, UKMHRA, WHO – GMP to mention a few.Our key market includes USA, Australia and European Union while Kenya scores amongst the best emerging markets.

ENZOFLAM PAN 40 ONDEM - MD

Bayer PharmaceuticalsBayer is a Life Science company with core

competencies in the areas of health care and agriculture. With our innovative products, we are contributing to �nding solutions to some of the major challenges of our time. Bayer is improving

people’s quality of life by preventing, alleviating and treating diseases.

The Pharmaceuticals Division focuses on prescription products, especially for cardiology and

women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and

ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary

contrast agents.For more information, please visit

www.pharma.bayer.com


Surgilinks Ltd “Your Excellent Link to Affordable Healthcare” “Surgilinks” Mombasa Road, P.O. Box 14461-‐00800 Nairobi -‐ Kenya. Tel: 6651465/6/7/8, Fax: 6651469 Email: [email protected] Website: http://www.surgilinksltd.com

Importers, Distributors, Wholesalers of

Pharmaceuticals Product

We are proud to be

Associated with

M.P.Shah Hospital

We are Agents for;




We are proud to be

Associated with

M.P.Shah Hospital

We are Agents for;




We are proud to be

Associated with

M.P.Shah Hospital

We are Agents for;

OTH

ERS

TOR

CH

STD

sV

IRA

L H

EPAT

ITIS

A R A Y O F H O P EPHARMACEUTICALS LIMITED

The triple action antacid“Raft”

s u s p e n s i o n

For faster relief from

Heart-burn and Acid R

(Dextromethorphan, Phenylephrine & Cetirizine)

Controls dry cough safelyA R A Y O F H O P E

PHARMACEUTICALS LIMITED

HIGHRIDGE PHARMACEUTICALS LTD.Amani Plaza, 3rd Parklands Ave., P.O. Box 32982 00600, Nairobi.

Telephone No.3741875/3755505/3752847/Fax No. 3753038E-mail: [email protected]; [email protected]

INTRODUCTION:

Highridge Pharmaceuticals Limited is a quality Pharmaceuticals, Laboratory Reagents, Rapid Diagnostic Items, Medical Consumables, Surgical items and other Medical accessories importer, exporter, distributor and wholesaler.

The business started in 1997 as a retail pharmacy. Over the years, the company has subsequently grown and extended its operational services to larger healthcare institutions, hence developing a fully-fledged Pharmacy & Poisons Board Kenya (PPB) certified wholesale division which commenced in November 2002. Ever since, we have endeavoured to provide our reputable clientele with the highest quality healthcare products and services in the Country today. The Chief Managers of our Company have a collective work experience of over 30 years in the Pharmaceutical, Laboratory, Surgical and Diagnostic supplies business throughout East and Central Africa.

Highridge Pharmaceuticals Ltd., therefore believes that it is a well-equipped and qualified establishment, having supplied and delivered quality healthcare products to all leading major institutions countrywide, including the Aga Khan University Hospitals (East Africa), Gertrudes Children’s Hospital, Kenyatta National Hospital (KNH), Kenya Medical Supplies Agency (KEMSA), Mission for Essential drugs and supplies (MEDS), The Kenya Red Cross, The Walter Reed Project, The Karen Hospital and the Nairobi Hospital to name a few. Hence, we feel that we are able to perform any contracts successfully & satisfactorily according to the client’s specific needs and requirements.

Highridge Pharmaceuticals Ltd aims to become one of the most prominent and reputable pharmaceutical & healthcare product distributor and service provider in the East African region. The Company’s policy of holding adequate stocks of all items on its expansive price list has generated a broader and more satisfied clientele base throughout the region. The management of the Company is therefore committed to fielding a proactive approach in meeting its client’s needs in order to maximize customer satisfaction.

We are the first company to have brought in Niche products including the lifesaving Lipholyn (Liposomal Amphotericin B) and Qurion (silver ionic solution for difficult to treat wounds), both of which were the first of its kind in the market. In addition to this, the company has also introduced Enzymatic Cleaners, Rust removers and Lubricants from USA to control hospital infection and maintain instruments and scopes to increase longevity and reduce repairs and replacement costs.

Hence from its humble beginnings, the business today has grown in stature attracting reputablehealthcare agencies, as well as creating new innovative avenues of business throughout the region.


WITH BEST COMPLIMENTS TO THE COMMITTEE

OF THE 5TH INFECTIOUS DISEASE

SYMPOSIUM 2016For more information, please contact: CIPLA KENYA Ltd. c/o Surgipharm Ltd., Nairobi, Kenya. Tel: 020 3749304

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

NOTES

M. P. SHAH HOSPITAL


__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

NOTES


__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

__________________________________________________________________________________________

NOTES


MR ANUP DAS DR CHRIS ABEID

LONY MURIITHI FATMA ABDIKOLI COLLINS

NEVILLE ODHIAMBO

SHAINA SHAHREBAH SIJENYI

MARREN CHUNGA SATANTAR SINGH

TOSEEF DIN

DR SURENDRA PATEL

THE SYMPOSIUM ORGANISING COMMITTEE


SPONSORS

NELNairobi Enterprises LimitedA R A Y O F H O P E

PHARMACEUTICALS LIMITED

The triple action antacid“Raft”

s u s p e n s i o n

For faster relief from

Heart-burn and Acid Reflux

Design & Layout byO.N.0726274657

HIGHRIDGE PHARMACEUTICALS LTD.Amani Plaza, 3rd Parklands Ave., P.O. Box 32982 00600, Nairobi.

Telephone No.3741875/3755505/3752847/Fax No. 3753038E-mail: [email protected]; [email protected]

INTRODUCTION:

Highridge Pharmaceuticals Limited is a quality Pharmaceuticals, Laboratory Reagents, Rapid Diagnostic Items, Medical Consumables, Surgical items and other Medical accessories importer, exporter, distributor and wholesaler.

The business started in 1997 as a retail pharmacy. Over the years, the company has subsequently grown and extended its operational services to larger healthcare institutions, hence developing a fully-fledged Pharmacy & Poisons Board Kenya (PPB) certified wholesale division which commenced in November 2002. Ever since, we have endeavoured to provide our reputable clientele with the highest quality healthcare products and services in the Country today. The Chief Managers of our Company have a collective work experience of over 30 years in the Pharmaceutical, Laboratory, Surgical and Diagnostic supplies business throughout East and Central Africa.

Highridge Pharmaceuticals Ltd., therefore believes that it is a well-equipped and qualified establishment, having supplied and delivered quality healthcare products to all leading major institutions countrywide, including the Aga Khan University Hospitals (East Africa), Gertrudes Children’s Hospital, Kenyatta National Hospital (KNH), Kenya Medical Supplies Agency (KEMSA), Mission for Essential drugs and supplies (MEDS), The Kenya Red Cross, The Walter Reed Project, The Karen Hospital and the Nairobi Hospital to name a few. Hence, we feel that we are able to perform any contracts successfully & satisfactorily according to the client’s specific needs and requirements.

Highridge Pharmaceuticals Ltd aims to become one of the most prominent and reputable pharmaceutical & healthcare product distributor and service provider in the East African region. The Company’s policy of holding adequate stocks of all items on its expansive price list has generated a broader and more satisfied clientele base throughout the region. The management of the Company is therefore committed to fielding a proactive approach in meeting its client’s needs in order to maximize customer satisfaction.

We are the first company to have brought in Niche products including the lifesaving Lipholyn (Liposomal Amphotericin B) and Qurion (silver ionic solution for difficult to treat wounds), both of which were the first of its kind in the market. In addition to this, the company has also introduced Enzymatic Cleaners, Rust removers and Lubricants from USA to control hospital infection and maintain instruments and scopes to increase longevity and reduce repairs and replacement costs.

Hence from its humble beginnings, the business today has grown in stature attracting reputablehealthcare agencies, as well as creating new innovative avenues of business throughout the region.

Health & Medicine

Symposium booklet 2016